Jessica Clymer
Overview
Explore the profile of Jessica Clymer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeo K, Macrae C, Gampel B, Ahrendsen J, Lidov H, Wright K, et al.
Neurooncol Adv
. 2024 Jul;
6(1):vdae097.
PMID: 38962753
Background: Choroid plexus tumors (CPTs) are rare, potentially aggressive CNS tumors with defined histologic criteria for grading. In recent years, several patients within our practice have demonstrated discordance between the...
2.
Groves A, Clymer J, Filbin M
Pharmaceuticals (Basel)
. 2022 Jun;
15(6).
PMID: 35745584
Pediatric brain tumors have surpassed leukemia as the leading cause of cancer-related death in children. Several landmark studies from the last two decades have shown that many pediatric brain tumors...
3.
Pearson A, Dubois S, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, et al.
Eur J Cancer
. 2021 Feb;
146:115-124.
PMID: 33601323
Based on biology and pre-clinical data, bromodomain and extra-terminal (BET) inhibitors have at least three potential roles in paediatric malignancies: NUT (nuclear protein in testis) carcinomas, MYC/MYCN-driven cancers and fusion-driven...
4.
Tsai J, Manoharan N, Alexandrescu S, Zimmerman M, Scully J, Chordas C, et al.
Pediatr Blood Cancer
. 2021 Feb;
68(8):e28930.
PMID: 33565268
Background: Ependymoma is the third most common malignant CNS tumor in children. Despite multimodal therapy, prognosis of relapsed ependymoma remains poor. Approaches to therapy for relapsed ependymoma are varied. We...
5.
Gupta S, Aitken J, Bartels U, Bhakta N, Bucurenci M, Brierley J, et al.
Lancet Oncol
. 2020 Sep;
21(9):e444-e451.
PMID: 32888473
Population-based cancer registries (PBCRs) generate measures of cancer incidence and survival that are essential for cancer surveillance, research, and cancer control strategies. In 2014, the Toronto Paediatric Cancer Stage Guidelines...
6.
Manoharan N, Choi J, Chordas C, Zimmerman M, Scully J, Clymer J, et al.
J Neurooncol
. 2020 Aug;
149(2):253-262.
PMID: 32780261
Purpose: Pediatric low-grade gliomas (pLGGs) are the most common CNS tumor of childhood and comprise a heterogenous group of tumors. Children with progressive pLGG often require numerous treatment modalities including...
7.
Lim M, Shulman D, Roberts H, Li A, Clymer J, Bona K, et al.
Cancer Med
. 2020 Aug;
9(18):6658-6666.
PMID: 32750219
Background: Off-label drug prescribing is common in pediatric clinical medicine, though the extent and impact of this practice in pediatric oncology has not yet been characterized. Methods: We completed a...
8.
Cacciotti C, Choi J, Alexandrescu S, Zimmerman M, Cooney T, Chordas C, et al.
J Neurooncol
. 2020 Jul;
149(1):113-122.
PMID: 32627129
Introduction: Immune checkpoint inhibition through PD-1 and CTLA-4 blockade has shown efficacy in some adult malignancies and generated interest in pediatrics, including central nervous system (CNS) tumors. We describe our...
9.
Eckerdt F, Clymer J, Bell J, Beauchamp E, Blyth G, Goldman S, et al.
Sci Rep
. 2019 Sep;
9(1):12822.
PMID: 31492956
Despite recent advances in the treatment of medulloblastoma, patients in high-risk categories still face very poor outcomes. Evidence indicates that a subpopulation of cancer stem cells contributes to therapy resistance...
10.
Eckerdt F, Bell J, Beauchamp E, Clymer J, Blyth G, Kosciuczuk E, et al.
Mol Cancer Res
. 2019 Mar;
17(6):1305-1315.
PMID: 30842251
Medulloblastoma is a highly malignant pediatric brain tumor associated with poor outcome. Developing treatments that target the cancer stem cell (CSC) population in medulloblastoma are important to prevent tumor relapse...